A New Name for Acomplia?
This article was originally published in RPM Report
Executive Summary
Sanofi-Aventis is facing a possible name change for rimonabant in the US market. For a much-anticipated primary care product like Acomplia, that's not good news. Sanofi has sent mixed signals as to whether FDA will accept "Acomplia" as the brand name for rimonabant, but all signs indicate that the company will have to choose an alternate name for the US market.